Replimune Group, Inc. balance sheet REPL

Annual Quarterly

As of Sep 30, 2026, Replimune Group, Inc. had total assets of $373.9 million and total liabilities of $169.2 million. Total assets were down 4.0% from a year earlier. Stockholders' equity was $204.8 million. It held $307.8 million in cash and investments against $127.2 million of total debt, net cash of $180.6 million. The current ratio, current assets divided by current liabilities, was 7.11.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line	FY 2027 Sep 30, 2026	FY 2026 Mar 31, 2026	FY 2025 Mar 31, 2025	FY 2024 Mar 31, 2024	FY 2023 Mar 31, 2023	FY 2022 Mar 31, 2022	FY 2021 Mar 31, 2021	FY 2019 Mar 31, 2020	FY 2019 Mar 31, 2019
Assets
Cash	308 +200.9%	209 +88.1%	111 +49.2%	74 -49.2%	147 +38.4%	106 -42.0%	183	60	26
Short-term investments	0 -100.0%	60 -83.9%	373 +7.6%	346 -20.7%	437 +50.8%	290 -1.4%	294	109	109
Cash and investments	308 -4.9%	269 -44.4%	484 +15.0%	421 -27.9%	583 +47.4%	396 -16.9%	476	169	135
Inventory	10	—	—	—	—	—	—	—	—
Total current assets	324 -2.9%	279 -43.7%	496 +14.3%	434 -26.8%	593 +46.7%	404 -16.5%	484	174	141
Property and equipment, net	11 -27.2%	13 -5.6%	14 +31.1%	10 +40.2%	7 -5.7%	8 +6.6%	7	7	12
Total assets	374 -4.0%	332 -39.7%	551 +13.0%	488 -24.6%	647 +40.2%	461 -15.1%	543	234	154
Liabilities and equity
Accounts payable	6 -6.9%	7 -46.5%	12 +383.4%	3 -51.9%	5 +43.7%	4 +58.5%	2	3	7
Total current liabilities	46 -13.9%	58 -6.6%	62 +54.2%	40 +19.6%	34 +63.0%	21 +42.7%	15	12	10
Total liabilities	169 +34.1%	166 +22.7%	135 +19.7%	113 +24.0%	91 +82.7%	50 +12.6%	44	50	16
Stockholders' equity	205 -22.2%	166 -60.0%	416 +11.0%	375 -32.6%	555 +35.0%	411 -17.5%	499	184	138
Debt
Debt due within a year	—	—	—	—	—	—	—	10	—
Long-term debt	100 +111.3%	83 +79.6%	46 +3.5%	45 +56.4%	29	—	—	—	—
Lease liabilities	27 -5.8%	28 -5.1%	30 -4.1%	31 -3.3%	32 -2.2%	33 -1.3%	33	32	8
Total debt	127 +66.6%	112 +46.5%	76 +0.4%	76 +24.9%	61 +85.0%	33 -23.8%	33	42	8
Net cash	181 -27.0%	157 -61.4%	408 +18.2%	345 -34.0%	523 +44.0%	363 -16.3%	443	127	127
Ratios
Current ratio	7.11x	4.79x	7.95x	10.72x	17.52x	19.46x	33.25x	14.68x	14.26x
Debt to equity	0.62x	0.67x	0.18x	0.20x	0.11x	0.08x	0.07x	0.23x	0.06x
Return on equity	-132.36%	-188.94%	-59.47%	-57.62%	-31.39%	-28.70%	-16.22%	-28.64%	-38.17%
Return on assets	-72.48%	-94.45%	-44.85%	-44.25%	-26.95%	-25.59%	-14.89%	-22.48%	-34.10%
Book value per share	2.16	2.01	5.39	6.10	9.80	8.69	10.71	5.01	4.35

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: REPL (Nasdaq)
Fiscal year ends: March 31
Incorporated in: DE
Headquarters: Woburn, MA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1737953

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.